BING NEWS:
  • Ahead of Alnylam's key heart disease readout, experts say Pfizer rival would be hard to displace
    There, Amvuttra faces a tough battle. In the phase 3 ATTR-ACT trial, tafamidis slashed the risk of death by 30% compared with placebo. At the time of the mortality analysis, 29.5% of patients who ...
    04/21/2024 - 11:55 pm | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News